[Federal Register Volume 89, Number 26 (Wednesday, February 7, 2024)]
[Notices]
[Page 8437]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-02436]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the cooperative agreement applications, the disclosure 
of which would constitute a clearly unwarranted invasion of personal 
privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial 
Implementation Cooperative Agreement (U44 Clinical Trial Required); 
NIAID Clinical Trial Planning Grants (R34 Clinical Trial Not 
Allowed); NIAID Clinical Trial Implementation Cooperative Agreement.
    Date: February 29, 2024.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3E70A, 
Rockville, MD 20892 (Video Assisted Meeting).
    Contact Person: Soheyla Saadi, Ph.D., Scientific Review Officer, 
Scientific Review Program, Division of Extramural Activities, 
National Institute of Allergy and Infectious Diseases, National 
Institutes of Health, 5601 Fishers Lane, Room 3E70A, Rockville, MD 
20852, (240) 669-5178, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: February 1, 2024.
Lauren A. Fleck,
Program Analyst,Office of Federal Advisory Committee Policy.
[FR Doc. 2024-02436 Filed 2-6-24; 8:45 am]
BILLING CODE 4140-01-P